Evan Loh, M.D. has been Paratek’s Chief Executive Officer since June 2019. Prior to that, Dr. Loh served in various roles including President, Chief Operating Officer, and Chief Medical Officer from 2014 until June 2019.
Dr. Loh has been a member of the Paratek Board of Directors since 2014. Prior to the merger with Transcept Pharmaceuticals, Dr. Loh had served as Chairman of the Board of Directors and Chief Medical Officer. Previously, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer. While at Pfizer, Dr. Loh’s responsibilities included scientific, operational, and strategic drug development oversight for all R&D pre-proof of concept development phase programs and leading global portfolio prioritization.
Dr. Loh joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President, Multiple Therapeutic Areas where he was responsible for global development strategy and clinical operational deliverables. At Wyeth, he led multiple successful global registration programs, including for Torisel and Tygacil. He currently serves on the Board of Directors of Windtree Therapeutics, Inc. Dr. Loh served as Chairman of the Antimicrobials Working Group (AWG), an industry leading coalition of biotech companies focused on antimicrobial development from 2019 to 2021, and currently serves on its Executive Committee. Dr. Loh served as a Director on the Board of Nivalis from 2012 until the completion of its sale to Alpine Immunotherapeutics in 2017.
Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine. Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women’s Hospital.
What is Evan Loh's net worth?
The estimated net worth of Evan Loh is at least $0.00 as of August 9th, 2023. Dr. Loh owns 1,327,981 shares of Eiger BioPharmaceuticals stock worth more than $0 as of April 26th. This net worth approximation does not reflect any other investments that Dr. Loh may own. Learn More about Evan Loh's net worth.
How do I contact Evan Loh?
Has Evan Loh been buying or selling shares of Eiger BioPharmaceuticals?
Evan Loh has not been actively trading shares of Eiger BioPharmaceuticals over the course of the past ninety days. Most recently, Evan Loh sold 66 shares of the business's stock in a transaction on Monday, March 15th. The shares were sold at an average price of $304.20, for a transaction totalling $20,077.20. Following the completion of the sale, the director now directly owns 333 shares of the company's stock, valued at $101,298.60. Learn More on Evan Loh's trading history.
Who are Eiger BioPharmaceuticals' active insiders?
Are insiders buying or selling shares of Eiger BioPharmaceuticals?
During the last twelve months, Eiger BioPharmaceuticals insiders bought shares 2 times. They purchased a total of 5,940 shares worth more than $44,170.20. The most recent insider tranaction occured on November, 2nd when Major Shareholder Richard A Kayne bought 779 shares worth more than $7,011.00. Insiders at Eiger BioPharmaceuticals own 4.2% of the company.
Learn More about insider trades at Eiger BioPharmaceuticals. Information on this page was last updated on 11/2/2023.
